These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20084973)

  • 1. [Clinical trial on safety of inactivated split influenza virus vaccine, Anflu in 2007-2008].
    Wang X; Liu Y; Zhao YW
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):443-6. PubMed ID: 20084973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu®.
    Liu Y; Wu JY; Wang X; Chen JT; Xia M; Hu W; Zou Y; Yin WD
    Hum Vaccin Immunother; 2014; 10(1):73-82. PubMed ID: 24104060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.
    Lambert SB; Chuk LM; Nissen MD; Nolan TM; McVernon J; Booy R; Heron L; Richmond PC; Walls T; Marshall HS; Reynolds GJ; Hartel GF; Hu W; Lai MH
    Influenza Other Respir Viruses; 2013 Sep; 7(5):676-85. PubMed ID: 23551933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study.
    Heinonen S; Silvennoinen H; Lehtinen P; Vainionpää R; Ziegler T; Heikkinen T
    Lancet Infect Dis; 2011 Jan; 11(1):23-9. PubMed ID: 21106443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.
    Choe YJ; Cho H; Kim SN; Bae GR; Lee JK
    Vaccine; 2011 Oct; 29(44):7727-32. PubMed ID: 21827815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea.
    Kim JH; Cho HY; Hennessey KA; Lee HJ; Bae GR; Kim HC
    Jpn J Infect Dis; 2012; 65(2):99-104. PubMed ID: 22446114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Safety Surveillance of Seasonal Quadrivalent Influenza Vaccines in English Primary Care: Interim Analysis.
    de Lusignan S; Dos Santos G; Byford R; Schuind A; Damaso S; Shende V; McGee C; Yonova I; Ferreira F
    Adv Ther; 2018 Aug; 35(8):1199-1214. PubMed ID: 29995300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
    Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus].
    Guo W; Xu J; Wu J; Zhao S; He H; Shi W; Yu D; Li J; Gao H; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug; 35(8):949-52. PubMed ID: 25376689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and immunogenicity on the formulation of trivalent split influenza vaccine among healthy people aged over 18 years].
    Wang P; Zhang XW; Song YF; Yin HB; Liu LJ; Che L; Li H; Liu Y; Chen JT
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Feb; 32(2):120-4. PubMed ID: 21518617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
    Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip.
    Delore V; Salamand C; Marsh G; Arnoux S; Pepin S; Saliou P
    Vaccine; 2006 Mar; 24(10):1586-92. PubMed ID: 16271424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.